Organigram Global Inc Revenue Growth Rates (OGI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Organigram Global Inc   (NASDAQ: OGI)
 

OGI's Revenue Growth by Quarter and Year

Organigram Global Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OGI Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 198.53
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 198.53

OGIs Annual Revenue
Organigram Global Inc 's Revenue in the fiscal year 2025 $ 198.53 millions
Organigram Global Inc 's Revenue in the fiscal year 2024 $ 122.44 millions
Organigram Global Inc 's Revenue in the fiscal year 2023 $ 111.69 millions
Organigram Global Inc 's Revenue in the fiscal year 2022 $ 114.65 millions
Organigram Global Inc 's Revenue in the fiscal year 2021 $ 62.46 millions




OGI Revenue fourth quarter 2025 Y/Y Growth Comment
Organigram Global Inc showed record Revenue increase in the fourth quarter 2025 with 62.15% from the fourth quarter 2025 2024, to $ 198.53 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue growth. While Organigram Global Inc ' s Revenue jump of 62.15% ranks overall at the positon no. 313 in the fourth quarter 2025.


OGI Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 62.15 % 9.62 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   62.15 % 9.62 % - -

Financial Statements
Organigram Global Inc 's fourth quarter 2025 Revenue $ 198.53 millions OGI's Income Statement
Organigram Global Inc 's fourth quarter 2024 Revenue $ 122.44 millions Quarterly OGI's Income Statement


OGI Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   62.15 % 9.62 % - -


Back to OGI Growth rate Comparisons >> Back to OGI Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #86
Overall #313

Revenue Y/Y Growth Statistics
High Average Low
62.15 % 35.89 % 9.62 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #86
Overall #313
Revenue Y/Y Growth Statistics
High Average Low
62.15 % 35.89 % 9.62 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Organigram Global Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OGI's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OGI's IV. Quarter Q/Q Revenue Comment


Organigram Global Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Aug 31 2022)		 12 Months Ending
(Aug 31 2021)
Cumulative Revenue 12 Months Ending $ 198.53 $ 122.44 $ 111.69 $ 114.65 $ 62.46
Y / Y Revenue Growth (TTM) 62.15 % 9.62 % -2.58 % 83.56 % -3.2 %
Year on Year Revenue Growth Overall Ranking # 2773 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 62.15 % 9.62 % -2.58 % 83.56 % -3.2 %
Seq. Revenue Growth (TTM) Overall Ranking # 2773 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Although Organigram Global Inc 's Annual Revenue growth year on year were below company's average 118.78% , Revenue announced in the Sep 30 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 62.15% year on year, from 9.62% in Sep 30 2024.

In the Healthcare sector 392 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2773.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 393
Overall # 2773

Revenue TTM Y/Y Growth Statistics
High Average Low
563.12 %
 118.78 %
-3.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 133
Sector # 393
S&P 500 # 2773
Cumulative Revenue growth Comment
Although Organigram Global Inc 's Annual Revenue growth year on year were below company's average 118.78% , Revenue announced in the Sep 30 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 62.15% year on year, from 9.62% in Sep 30 2024.

In the Healthcare sector 392 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2773.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 393
Overall # 2773

Revenue TTM Y/Y Growth Statistics
High Average Low
563.12 %
118.78 %
-3.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 133
Sector # 393
S&P 500 # 2773




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OGI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Tonix Pharmaceuticals Holding Corp 108.75%$ 108.753 millions
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions
Caribou Biosciences Inc 89.74%$ 89.745 millions
Argenx Se89.08%$ 89.078 millions
Sangamo Therapeutics Inc 88.43%$ 88.425 millions
Agios Pharmaceuticals Inc 86.09%$ 86.086 millions
Oculis Holding Ag85.72%$ 85.722 millions
Alnylam Pharmaceuticals Inc 84.95%$ 84.945 millions
Day One Biopharmaceuticals Inc 83.92%$ 83.915 millions
Neuronetics Inc 82.17%$ 82.169 millions
Arcutis Biotherapeutics Inc 81.48%$ 81.478 millions
Aclarion Inc 80.59%$ 80.590 millions
X4 Pharmaceuticals Inc79.08%$ 79.079 millions
Intellia Therapeutics Inc 78.79%$ 78.787 millions
Envoy Medical Inc 78.57%$ 78.571 millions
Organogenesis Holdings Inc 78.13%$ 78.126 millions
Tg Therapeutics Inc 78.00%$ 78.004 millions
Eton Pharmaceuticals Inc 77.14%$ 77.140 millions
Trisalus Life Sciences Inc 76.95%$ 76.954 millions
Co diagnostics Inc 76.74%$ 76.743 millions
Ss Innovations International Inc76.54%$ 76.537 millions
Cellectis S a 75.76%$ 75.760 millions
Fennec Pharmaceuticals Inc 73.84%$ 73.842 millions
Travere Therapeutics Inc 73.41%$ 73.410 millions
Inspiremd Inc 69.30%$ 69.299 millions
Viridian Therapeutics Inc 68.06%$ 68.056 millions
Sol gel Technologies Ltd 68.04%$ 68.036 millions
Novavax inc 66.61%$ 66.615 millions
Beyond Air Inc 65.61%$ 65.605 millions


About Organigram Global Inc Revenue Growth Rates (OGI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Organigram Global Inc (CIK 1620737).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-057233
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Organigram Global Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.